#Istanbul #Turkey #Biologics #Bambusa Therapeutics #BBT002

Bambusa Therapeutics Presents Positive Results for BBT002

Bambusa Therapeutics, Inc., a biotechnology firm focused on developing next-generation bispecific antibodies, recently shared positive preliminary data from their BBT002 Phase 1 trial during the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Istanbul, Turkey. This data highlights BBT002’s potential as a promising new treatment for Type 2 inflammatory diseases.

BBT002 is engineered as a long-acting bispecific antibody targeting two well-studied components: IL-4Rα and IL-5. These components play crucial roles in inflammatory pathways, particularly in respiratory diseases. The trial sought to assess the safety and tolerability of BBT002 in healthy volunteers through a multiple ascending dose format.

Encouraging Findings

The results presented showed that BBT002 successfully maintained rapid, deep, and lasting biomarker effects for an extended period. Notably, the treatment demonstrated a half-life of approximately 29.4 days, enabling potential for less frequent dosing intervals, which could be crucial for patient adherence and improved management of chronic conditions.

Among the biomarkers assessed, eosinophil levels—indicative of airway inflammation—saw significant reductions for over eight weeks after administration. Furthermore, measurements of TARC, a key inflammatory chemokine, showed comparable decreases, confirming the therapy’s potential in managing Type 2 inflammation in respiratory diseases.

Another important biomarker, pSTAT6, showed complete and sustained inhibition post-treatment, demonstrating BBT002's efficacy at the molecular level. These results reinforce the idea that BBT002 could lead to a more comprehensive approach to controlling various inflammatory conditions.

Safety Profile

From a safety perspective, BBT002 was found to be well-tolerated across all dosage groups in the study, which is a significant consideration when evaluating new therapies. Additionally, the study noted low incidences of anti-drug antibodies, suggesting that immunogenicity may not pose a significant risk in this context, which is crucial for long-term therapies.

Dr. Thang Ho, Chief Development Officer at Bambusa Therapeutics, commented on the promising nature of the findings, emphasizing their potential impact on addressing inflammation driven by multiple mechanisms simultaneously. This could pave the way for better treatment options in respiratory and other eosinophil-related conditions.

Next Steps

As the Phase 1 trial progresses, Bambusa is also planning ongoing proof-of-concept studies in patients with chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP). Topline results from these studies are expected by late 2026 and early 2027, respectively. These studies aim to further elucidate the benefits of BBT002 in a broader patient population, informing its eventual clinical application.

In parallel bouts of research, Bambusa is advancing their first-in-class BBT001 program aimed at atopic dermatitis, seeking to extend its therapeutic portfolio in managing various inflammatory disorders.

Conclusion

With the presentations at EAACI 2026, Bambusa Therapeutics successfully showcased BBT002's potential not just as a treatment for allergies but also as a versatile option for multiple inflammation-driven diseases. As the clinical data continues to accumulate, it positions Bambusa at the forefront of innovation in treating chronic inflammation—a pressing global health challenge.

For more details on BBT002 and its exciting potential, please visit Bambusa Therapeutics' website.